Immunoexpression of PAX 8 in endometrial cancer: Relation to high-grade carcinoma and p53

International Journal of Gynecological Pathology

Volumn 30, Issue 6, 2011, Pages 569-575

  Brunner, Andreas H ^a   Riss, Paul ^a   Heinze, Georg ^b   Meltzow, Elisabeth ^b   Brustmann, Hermann ^a  

^a Landesklinikum Thermenregion Moedling/Vienna ^*  (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Endometrial carcinoma; Immunohistochemistry; p53; PAX 8

Indexed keywords

PARAFFIN; PROTEIN P53; TRANSCRIPTION FACTOR PAX8;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

AGED; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PAIRED BOX TRANSCRIPTION FACTORS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80053938125     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0b013e31821ac6c3     Document Type: Article

References (23)

1. Chi N, Epstein JA. Getting your PAX straight: PAX proteins in development and disease. Trends Genet 2002;18:41-7. (Pubitemid 34031857)
2. Stoykova A, Gruss P. Roles of PAX genes in developing and adult brain as suggested by expression patterns. J Neurosci 1994;14:1395-12.
3. Stuart ET, Haffner R, Oren M, et al. Loss of p 53 function through PAX-mediated transcriptional repression. EMBO J 1995;14:5638-45.
4. Poleev A, Fickenscher H, Mundlos S, et al. PAX 8, a human paired box gene: isolation and expression in developing thyroid, kidney and Wilms' tumors. Development 1992;116:611-23.
5. Mittag J, Winterhager E, Bauer K, et al. Congenital hypothyroid female PAX 8-deficient mice are infertile despite thyroid hormone replacement therapy. Endocrinology 2007; 148:719-25. (Pubitemid 46143173)
6. De Felice M, Di Lauro R. Thyroid development and its disorders: genetics and molecular mechanisms. Endocr Rev 2004;25:722-46. (Pubitemid 39362295)
7. Castro P, Rebocho AP, Soares RJ, et al. PAX 8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 2006;91: 213-20. (Pubitemid 43069140)
8. Gokden N, GokdenM, Phan DC, et al. The utility of PAX-2 in distinguishing metastatic clear cell renal cell carcinoma from its morphologic mimics: an immunohistochemical study with comparison to renal cell carcinoma marker. Am J Surg Pathol 2008;32:1462-7.
9. Mazal PR, Schaufler R, Altenhuber-Müller R, et al. Derivation of nephrogenic adenomas from renal tubular cells in kidneytransplant recipients. N Engl J Med 2002;347:653-9. (Pubitemid 34970868)
10. Tong GX, Melamed J, Mansukhani M, et al. PAX 2: a reliable marker for nephrogenic adenoma. Mod Pathol 2006;19: 356-3.
11. Lotan TL, Ye H, Melamed J, et al. Immunohistochemical Panel to identify the primary site of invasive micropapillary carcinoma. Am J Surg Pathol 2009;33:1037-41.
12. Nonaka D, Chiriboga L, Soslow RA. Expression of PAX 8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol 2008;32:1566-71.
13. Mutch DG. The New FIGO staging system for cancers of the vulva, cervix, endometrium, and sarcomas. Gynecol Oncol 2009;115:325-8.
14. Nucci MR, Oliva E. Gynecologic Pathology. London: Elsevier Churchill Livingstone; 2009.
15. Silverberg SG, Kurman RJ. Atlas of Tumor Pathology. Tumors of the Uterine Corpus and Gestational Trophoblastic Disease, Third Series, Fascicle 3. Washington, DC: Armed Forces Institute of Pathology; 1992.
16. Alkushi A, Köbel M, Kalloger SE, et al. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. Int J Gynecol Pathol 2010;29:343-50.
17. Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 6th Annual Report on the results of treatment in gynaecological cancer. Int J Gynecol Obstet 2006; 95:105-43.
18. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Amer Statist Assn 1958;53:457-81.
19. Cox DR. Regression models and life-tables (with discussion). J R Statist Soc, Series B 1972;34:187-220.
20. Bowen NJ, Logani S, Dickerson EB, et al. Emerging roles for PAX 8 in ovarian cancer and endosalpingeal development. Gynecol Oncol 2007;104:331-7. (Pubitemid 46135661)
21. Tacha D, Cheng D, Henshall-Powell RL. Expression of PAX 8 in normal and neoplastic tissues: a comprehensive IHC analysis. Mod Pathol 2010;23:222A.
22. Yemelyanova A, Gown AM, Ronett BM, et al. PAX 8 expression in uterine adenocarcinoma: immunohistochemical analysis of 94 cases. Mod Pathol 2010;23:269A.
23. Köbel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. Int J Gynecol Pathol 2010;29:203-11.